REYVOW Drug Patent Profile
✉ Email this page to a colleague
When do Reyvow patents expire, and when can generic versions of Reyvow launch?
Reyvow is a drug marketed by Eli Lilly And Co and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.
This drug has eighty-five patent family members in forty-three countries.
The generic ingredient in REYVOW is lasmiditan succinate. One supplier is listed for this compound. Additional details are available on the lasmiditan succinate profile page.
DrugPatentWatch® Generic Entry Outlook for Reyvow
Reyvow was eligible for patent challenges on January 31, 2024.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be December 5, 2037. This may change due to patent challenges or generic licensing.
There is one Paragraph IV patent challenge for this drug. This may lead to patent invalidation or a license for generic production.
Indicators of Generic Entry
Summary for REYVOW
International Patents: | 85 |
US Patents: | 2 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 84 |
Patent Applications: | 72 |
Drug Prices: | Drug price information for REYVOW |
What excipients (inactive ingredients) are in REYVOW? | REYVOW excipients list |
DailyMed Link: | REYVOW at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for REYVOW
Generic Entry Date for REYVOW*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Anatomical Therapeutic Chemical (ATC) Classes for REYVOW
Paragraph IV (Patent) Challenges for REYVOW
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
REYVOW | Tablets | lasmiditan succinate | 50 mg and 100 mg | 211280 | 1 | 2024-01-31 |
US Patents and Regulatory Information for REYVOW
REYVOW is protected by two US patents and one FDA Regulatory Exclusivity.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of REYVOW is ⤷ Try a Trial.
This potential generic entry date is based on patent ⤷ Try a Trial.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting REYVOW
Compositions and methods related to pyridinoylpiperidine 5-HT.sub.1F agonists
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: ACUTE TREATMENT OF MIGRAINE
Pyridinoylpiperidines as 5-HT.sub.1F agonists
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: ACUTE TREATMENT OF MIGRAINE
FDA Regulatory Exclusivity protecting REYVOW
NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷ Try a Trial
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eli Lilly And Co | REYVOW | lasmiditan succinate | TABLET;ORAL | 211280-001 | Jan 31, 2020 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Eli Lilly And Co | REYVOW | lasmiditan succinate | TABLET;ORAL | 211280-003 | Dec 18, 2020 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Eli Lilly And Co | REYVOW | lasmiditan succinate | TABLET;ORAL | 211280-002 | Jan 31, 2020 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Eli Lilly And Co | REYVOW | lasmiditan succinate | TABLET;ORAL | 211280-003 | Dec 18, 2020 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Eli Lilly And Co | REYVOW | lasmiditan succinate | TABLET;ORAL | 211280-001 | Jan 31, 2020 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for REYVOW
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Eli Lilly And Co | REYVOW | lasmiditan succinate | TABLET;ORAL | 211280-001 | Jan 31, 2020 | ⤷ Try a Trial | ⤷ Try a Trial |
Eli Lilly And Co | REYVOW | lasmiditan succinate | TABLET;ORAL | 211280-002 | Jan 31, 2020 | ⤷ Try a Trial | ⤷ Try a Trial |
Eli Lilly And Co | REYVOW | lasmiditan succinate | TABLET;ORAL | 211280-003 | Dec 18, 2020 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for REYVOW
When does loss-of-exclusivity occur for REYVOW?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 17373784
Estimated Expiration: ⤷ Try a Trial
Brazil
Patent: 2019010934
Estimated Expiration: ⤷ Try a Trial
Canada
Patent: 43772
Estimated Expiration: ⤷ Try a Trial
Chile
Patent: 19001426
Estimated Expiration: ⤷ Try a Trial
China
Patent: 0291079
Estimated Expiration: ⤷ Try a Trial
Patent: 5385893
Estimated Expiration: ⤷ Try a Trial
Patent: 5385894
Estimated Expiration: ⤷ Try a Trial
Colombia
Patent: 19005290
Estimated Expiration: ⤷ Try a Trial
Costa Rica
Patent: 190251
Estimated Expiration: ⤷ Try a Trial
Croatia
Patent: 0211557
Estimated Expiration: ⤷ Try a Trial
Cyprus
Patent: 24540
Estimated Expiration: ⤷ Try a Trial
Denmark
Patent: 51617
Estimated Expiration: ⤷ Try a Trial
Dominican Republic
Patent: 019000139
Estimated Expiration: ⤷ Try a Trial
Ecuador
Patent: 19040190
Estimated Expiration: ⤷ Try a Trial
Eurasian Patent Organization
Patent: 1991112
Estimated Expiration: ⤷ Try a Trial
European Patent Office
Patent: 51617
Estimated Expiration: ⤷ Try a Trial
Hungary
Patent: 56820
Estimated Expiration: ⤷ Try a Trial
Israel
Patent: 6598
Estimated Expiration: ⤷ Try a Trial
Japan
Patent: 20500936
Estimated Expiration: ⤷ Try a Trial
Patent: 22000451
Estimated Expiration: ⤷ Try a Trial
Patent: 23123678
Estimated Expiration: ⤷ Try a Trial
Jordan
Patent: 0190129
Estimated Expiration: ⤷ Try a Trial
Lithuania
Patent: 51617
Estimated Expiration: ⤷ Try a Trial
Malaysia
Patent: 6855
Estimated Expiration: ⤷ Try a Trial
Mexico
Patent: 19006520
Estimated Expiration: ⤷ Try a Trial
Patent: 21014139
Estimated Expiration: ⤷ Try a Trial
Moldova, Republic of
Patent: 51617
Estimated Expiration: ⤷ Try a Trial
Morocco
Patent: 920
Estimated Expiration: ⤷ Try a Trial
New Zealand
Patent: 2906
Estimated Expiration: ⤷ Try a Trial
Peru
Patent: 191134
Estimated Expiration: ⤷ Try a Trial
Philippines
Patent: 019501252
Estimated Expiration: ⤷ Try a Trial
Poland
Patent: 51617
Estimated Expiration: ⤷ Try a Trial
Portugal
Patent: 51617
Estimated Expiration: ⤷ Try a Trial
Serbia
Patent: 415
Estimated Expiration: ⤷ Try a Trial
Slovenia
Patent: 51617
Estimated Expiration: ⤷ Try a Trial
South Africa
Patent: 1903449
Estimated Expiration: ⤷ Try a Trial
South Korea
Patent: 190075130
Estimated Expiration: ⤷ Try a Trial
Patent: 210102497
Estimated Expiration: ⤷ Try a Trial
Patent: 230008257
Estimated Expiration: ⤷ Try a Trial
Spain
Patent: 89476
Estimated Expiration: ⤷ Try a Trial
Taiwan
Patent: 71290
Estimated Expiration: ⤷ Try a Trial
Patent: 1833097
Estimated Expiration: ⤷ Try a Trial
Tunisia
Patent: 19000174
Estimated Expiration: ⤷ Try a Trial
Ukraine
Patent: 4433
Estimated Expiration: ⤷ Try a Trial
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering REYVOW around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Colombia | 2019005290 | Composiciones y métodos relacionados con agonistas de piridinoilpiperidina 5-ht1f | ⤷ Try a Trial |
Brazil | 112019010934 | composições e métodos relacionados a agonistas de piridinoilpiperidina 5-ht1f | ⤷ Try a Trial |
Portugal | 1492786 | ⤷ Try a Trial | |
Poland | 210019 | ⤷ Try a Trial | |
Eurasian Patent Organization | 007966 | ПИРИДИНОИЛПИПЕРИДИНЫ КАК АГОНИСТЫ 5-HT (PYRIDINOYLPIPERIDINES AS 5-HTAGONISTS) | ⤷ Try a Trial |
>Country | >Patent Number | >Title | >Estimated Expiration |